Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the "Company") for medical reasons. The Company elected Hana Chen-Walden, currently a member of the Company's Medical Advisory Board, to fill the vacancy created by Dr. Esber's resignation.

Dr. Hana Chen-Walden, M.D. is an Endocrinologist and has specialized in regulatory affairs in the pharmaceutical industry in the US and Europe. Dr. Chen-Walden has more than 35 years of regulatory experience with the EMEA and in individual European countries. Since 2004 to present, Dr. Chen-Walden consulted for European Clinical and Regulatory Consultancy in medical monitoring, quality assurance and regulatory input for clinical studies in the fields of oncology, cardiology, diabetes, neurology, respiratory diseases and medical devices. Dr. Chen Walden received her Doctorate of Medicine from University of Tel Aviv, Israel. Dr. Chen-Walden has practiced medicine in Germany and France. Our board of directors believes that Dr. Chen-Walden's expertise and experience in practicing medicine, her perspective, depth and background in medical monitoring and quality assurance, and her leadership in regulatory affairs provide her with the qualifications and skills to serve on our board of directors.

Compensation Arrangements with Dr. Chen-Walden

Dr. Chen-Walden is not currently receiving any compensation for her service as member of the Company's Medical Advisory Board. She will not receive any cash compensation as Director.

© Edgar Online, source Glimpses